AdPharma

AdPharma is a South Korean pharmaceutical company, operating as a subsidiary of Yuhan Corporation, that focuses on the development of Incrementally Modified Drugs (IMDs) and fixed-dose combination (FDC) therapies. The company's primary strategy involves enhancing the clinical value of established active pharmaceutical ingredients through novel formulations that improve patient adherence and therapeutic outcomes. AdPharma's portfolio targets major chronic conditions, including cardiovascular diseases, metabolic disorders, and central nervous system ailments like Alzheimer's disease. Their lead programs include AD-201, a triple combination for hypertension and dyslipidemia, and AD-101, which combines donepezil with meclizine to mitigate gastrointestinal side effects in Alzheimer's patients. By leveraging Yuhan's extensive commercial infrastructure, AdPharma aims to rapidly bring optimized treatment options to the global market.